Grantham, Mayo, Van Otterloo & Co (GMO)
TEVA icon

Grantham, Mayo, Van Otterloo & Co (GMO)’s Teva Pharmaceuticals TEVA Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,337
Closed -$257K – 655
2025
Q2 		$257K Buy
+15,337
New +$247K ﹤0.01% 576
2024
Q4 		– Sell
-18,792
Closed -$339K – 612
2024
Q3 		$339K Sell
18,792
-2,036,723
-99% -$35.6M ﹤0.01% 516
2024
Q2 		$33.4M Sell
2,055,515
-377,752
-16% -$5.82M 0.11% 123
2024
Q1 		$34.3M Sell
2,433,267
-846,794
-26% -$10.7M 0.12% 119
2023
Q4 		$34.2M Sell
3,280,061
-184,146
-5% -$1.72M 0.15% 119
2023
Q3 		$35.3M Sell
3,464,207
-85,576
-2% -$797K 0.17% 110
2023
Q2 		$26.7M Buy
3,549,783
+301,583
+9% +$2.45M 0.12% 149
2023
Q1 		$28.7M Sell
3,248,200
-502,100
-13% -$4.96M 0.15% 146
2022
Q4 		$34.2M Buy
3,750,300
+437,400
+13% +$3.82M 0.18% 119
2022
Q3 		$26.7M Sell
3,312,900
-151,800
-4% -$1.34M 0.15% 133
2022
Q2 		$26.1M Sell
3,464,700
-11,400
-0.3% -$99.3K 0.14% 156
2022
Q1 		$32.6M Buy
3,476,100
+700,500
+25% +$5.85M 0.16% 110
2021
Q4 		$22.2M Sell
2,775,600
-30,100
-1% -$272K 0.11% 158
2021
Q3 		$27.3M Buy
2,805,700
+252,800
+10% +$2.37M 0.14% 131
2021
Q2 		$25.3M Buy
2,552,900
+559,000
+28% +$5.92M 0.13% 137
2021
Q1 		$23M Buy
1,993,900
+178,300
+10% +$2.04M 0.13% 131
2020
Q4 		$17.5M Buy
+1,815,600
New +$17.4M 0.11% 131
2019
Q1 		– Sell
-15,000
Closed -$231K – 744
2018
Q4 		$231K Buy
+15,000
New +$308K ﹤0.01% 501
2018
Q3 		– Sell
-36,900
Closed -$897K – 584
2018
Q2 		$897K Buy
+36,900
New +$753K 0.01% 377
2017
Q1 		– Sell
-14,950
Closed -$542K – 641
2016
Q4 		$542K Sell
14,950
-321,750
-96% -$12.8M ﹤0.01% 406
2016
Q3 		$15.5M Buy
336,700
+49,400
+17% +$2.58M 0.07% 179
2016
Q2 		$14.4M Buy
+287,300
New +$15.3M 0.06% 200
2014
Q3 		– Sell
-11,400
Closed -$598K – 476
2014
Q2 		$598K Sell
11,400
-2,000
-15% -$102K ﹤0.01% 433
2014
Q1 		$708K Buy
+13,400
New +$619K ﹤0.01% 496

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s TEVA Position: Q3 2025 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Teva Pharmaceuticals (TEVA) in Q3 2025, closing a stake of 15,337 shares — an estimated $257K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in TEVA in Q1 2014 and held it in 24 quarters. The position peaked at $35.3M in Q3 2023. 550 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Teva Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 15,337 Teva Pharmaceuticals shares in Q3 2025, an estimated $257K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 24 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Teva Pharmaceuticals position peaked at $35.3M in Q3 2023.
  • 550 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2025.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q3 2025, filed 13 Nov 2025.